Hexamethylquercetagetin
Based on 1 Customer Validation
Hexamethylquercetagetin (Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone) is an orally active NF-κB inhibitor. Hexamethylquercetagetin inhibits NF-κB-derived luciferase activity, reduces phosphorylated p65 and IκBα, Cyclin D1, Bcl-2 and blocks TNFα-induced NF-κB activation. Hexamethylquercetagetin inhibits survival and proliferation of cervical carcinoma cells. Hexamethylquercetagetin suppresses tumor volume and weight in BALB/c nude mouse xenograft models of cervical carcinoma. Hexamethylquercetagetin can be used for the research of cancer, such as cervical carcinoma.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 1251-84-9
- Formula: C21H22O8
- Molecular Weight:402.39
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
IC50 & Target
[1]|
Bcl-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Col2 | ED50 |
>20 μg/mL
Compound: 2
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 12828478] |
| HL-60 | IC50 |
20.59 μM
Compound: VII, HexaMF
|
Antiproliferative activity against HL60 after 24 hrs
Antiproliferative activity against HL60 after 24 hrs
|
[PMID: 17391969] |
| HUVEC | ED50 |
>20 μg/mL
Compound: 2
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 12828478] |
| KB | ED50 |
>20 μg/mL
Compound: 2
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 12828478] |
| LNCaP | ED50 |
>20 μg/mL
Compound: 2
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 12828478] |
| Lu1 | ED50 |
>20 μg/mL
Compound: 2
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 12828478] |
| TERT-RPE1 | ED50 |
>20 μg/mL
Compound: 2
|
Cytotoxicity against human telomerase reverse transcriptase expressing RPE1 cells
Cytotoxicity against human telomerase reverse transcriptase expressing RPE1 cells
|
[PMID: 12828478] |
In Vitro
Hexamethylquercetagetin (25-100 μM; 24 h) potently suppresses NF-κB-driven luciferase activity in Ca Ski and C-33 A cervical carcinoma cells[2].
Hexamethylquercetagetin (25-100 μM; 24 h) inhibits viability of Ca Ski, C-33 A, HeLa, and SiHa cervical carcinoma cells in a concentration-dependent manner, but does not affect viability of NIH3T3 normal fibroblast cells[2].
Hexamethylquercetagetin (25-100 μM; 24 h) inhibits NF-κB signaling in Ca Ski and C-33 A cervical carcinoma cells by reducing concentration-dependent expression of p-p65, p-IκBα, Cyclin D1, and Bcl-2[2].
Hexamethylquercetagetin (25-100 μM; 4 h pre-incubation) suppresses TNFα-induced NF-κB activation in Ca Ski and C-33 A cervical carcinoma cells, as measured by reduced p-p65 expression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human cervical carcinoma Ca Ski, C-33 A, HeLa, SiHa cells, normal mouse fibroblast NIH3T3 cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited cell viability in a concentration-dependent manner in Ca Ski, C-33 A, HeLa, and SiHa cervical carcinoma cells.
No significant toxicity was observed in NIH3T3 normal fibroblast cells at any tested concentration.
-
Cell Line:human cervical carcinoma Ca Ski, C-33 A cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Downregulated the relative expression of phosphorylated p65 (p-p65) and phosphorylated IκBα (p-IκBα) in both Ca Ski and C-33 A cells in a concentration-dependent manner, with significant reductions at all tested concentrations relative to untreated cells.
Markedly downregulated the NF-κB downstream proteins Cyclin D1 and Bcl-2 in a concentration-dependent manner in both cell lines.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice with Ca Ski cells xenograft[2]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 15 days
-
Result:Significantly reduced tumor volume and tumor weight in a concentration-dependent manner compared to vehicle controls.
Significantly downregulated the relative protein expression of phosphorylated NF-κB p65 (p-p65) in tumor tissue compared to vehicle controls, with the 100 mg/kg dose showing greater inhibition than the 50 mg/kg dose.
Chemical Information
-
CAS No. 1251-84-9
-
Appearance Solid
-
Molecular Weight 402.39
-
Formula C21H22O8
-
Color Off-white to light yellow
-
SMILES
O=C1C(OC)=C(C2=CC=C(OC)C(OC)=C2)OC3=CC(OC)=C(OC)C(OC)=C13
-
Synonyms
Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 27.5 mg/mL (68.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4852 mL | 12.4258 mL | 24.8515 mL | 62.1288 mL |
| 5 mM | 0.4970 mL | 2.4852 mL | 4.9703 mL | 12.4258 mL | |
| 10 mM | 0.2485 mL | 1.2426 mL | 2.4852 mL | 6.2129 mL | |
| 15 mM | 0.1657 mL | 0.8284 mL | 1.6568 mL | 4.1419 mL | |
| 20 mM | 0.1243 mL | 0.6213 mL | 1.2426 mL | 3.1064 mL | |
| 25 mM | 0.0994 mL | 0.4970 mL | 0.9941 mL | 2.4852 mL | |
| 30 mM | 0.0828 mL | 0.4142 mL | 0.8284 mL | 2.0710 mL | |
| 40 mM | 0.0621 mL | 0.3106 mL | 0.6213 mL | 1.5532 mL | |
| 50 mM | 0.0497 mL | 0.2485 mL | 0.4970 mL | 1.2426 mL | |
| 60 mM | 0.0414 mL | 0.2071 mL | 0.4142 mL | 1.0355 mL |